Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech (KRYS)
NASDAQ:KRYS
Holding KRYS?
Track your performance easily
KRYS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$93.95 - $219.34
Previous Close$195.12
Volume202.92K
Average Volume (3M)395.20K
Market Cap
$5.61B
Enterprise Value$5.06B
Total Cash (Recent Filing)$559.61M
Total Debt (Recent Filing)$7.69M
Price to Earnings (P/E)53.4
Beta0.87
Next Earnings
Nov 04, 2024EPS Estimate
$1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.65
Shares Outstanding28,729,950
10 Day Avg. Volume171,581
30 Day Avg. Volume395,196
Standard Deviation0.16
R-Squared0.08
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)6.69
Price to Sales (P/S)33.74
Price to Cash Flow (P/CF)-336.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue30.41
Enterprise Value/Gross Profit106.22
Enterprise Value/Ebitda24.50
Forecast
1Y Price Target
$209.40Price Target Upside7.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Krystal Biotech News
PremiumCompany Announcements
Krystal Biotech Reports Promising KB301 Phase 1 Results
Bulls Say, Bears Say
Bulls Say
Financial PerformanceKrystal Biotech's strong financial foundation is highlighted by its robust cash position, providing a solid base for future operations and investments.
Gene Therapy AdvancementsKrystal Biotech's HSV-1 gene therapy vector shows promise for posterior eye delivery, offering an innovative avenue for further therapeutic developments.
Pipeline PotentialKrystal Biotech expects to deliver data readouts showcasing the breadth and potential of its proprietary HSV-1 based gene delivery platform, signaling future growth and expansion into new therapeutic areas.
Bears Say
EarningsKrystal announced 1Q24 results, posting EPS of $0.03 compared to an estimate of $0.09 and consensus of $0.27.
Financial PerformanceThere was an expected, one-time headwind due to the permanent J code switch, which had significant impacts on reimbursement and an expected negative impact on revenue projections.
Management And OperationsConcerns for the commercial execution in the absence of a Chief Commercial Officer.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $93.95 and its highest was $219.34 in the past 12 months.
What is Krystal Biotech’s market cap?
Currently, no data Available
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is Nov 04, 2024 which is in 65 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on Aug 05, 2024. The company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.733 by -$0.203.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is $1.03.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 28,729,950 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $0.53 in its last earnings report, missing expectations of $0.733. Following the earnings report the stock price went down -5.851%.
Which hedge fund is a major shareholder of Krystal Biotech?
Among the largest hedge funds holding Krystal Biotech’s share is Woodline Partners LP. It holds Krystal Biotech’s shares valued at 54M.
---
Krystal Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$209.40 (7.32% Upside)
$209.40 (7.32% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 26.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.01%
12-Months-Change
Fundamentals
Return on Equity
14.20%
Trailing 12-Months
Asset Growth
34.16%
Trailing 12-Months
Company Description
Krystal Biotech
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
---
KRYS Company Deck
---
KRYS Earnings Call
Q2 2024
0:00 / 0:00
---
KRYS Stock 12 Month Forecast
Average Price Target
$209.40
▲(7.32% Upside)
Technical Analysis
Best Analysts Covering KRYS
1 Year
1 Year Success Rate
14/14 ratings generated profit
1 Year Average Return
+52.16%
reiterated a buy rating 27 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +52.16% per trade.
---